Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
22 hedge funds and large institutions have $2.84M invested in Cyclo Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 1 closing their positions.
0.28% more ownership
Funds ownership: 7.53% → 7.82% (+0.28%)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
6% less capital invested
Capital invested by funds: $3.01M → $2.84M (-$166K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$32.6K |
| 3 |
BlackRock
New York
|
+$29.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$48.3K |
| 2 |
Renaissance Technologies
New York
|
-$11.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.09K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$230 |
| 5 |
CFM
Catalyst Funds Management
Sydney NSW,
Australia
|
-$93 |
CYTH Hedge Fund Activity: Q2 2024 in Review
22 of the 6,939 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q2 2024, worth a combined $2.84M — down 5.5% from $3.01M a quarter earlier.
Fund positioning in CYTH was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $66K. The largest seller was EPIQ Capital Group, cutting an estimated $48.3K.
- 22 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $2.84M of Cyclo Therapeutics, Inc. Common Stock stock for Q2 2024, down 5.5% quarter-over-quarter.
- 1 fund opened new Cyclo Therapeutics, Inc. Common Stock positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q2 2024 was Vanguard Group, an estimated $66K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q2 2024 was EPIQ Capital Group, an estimated $48.3K sold.
Based on aggregated 13F filings for Q2 2024.